Get the Stockscreener App
78.15
0.71%
0.4965
Apogee Therapeutics Inc stock is traded at $78.15, with a volume of 296.47K.
It is up +0.71% in the last 24 hours and up +1.46% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$77.65
Open:
$77.47
24h Volume:
296.47K
Relative Volume:
0.33
Market Cap:
$5.33B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-28.37
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
-0.06%
1M Performance:
+1.46%
6M Performance:
+105.04%
1Y Performance:
+91.16%
1-Day Range:
$77.39
$80.00
1-Week Range:
$75.02
$80.34
52-Week Range:
$26.20
$80.99
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
78.01 | 5.31B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.45 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.88 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
806.88 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
368.39 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.35 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Published on: 2026-01-13 09:29:07 - Улправда
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones - Yahoo Finance
Positive Asthma Data and I&I Pipeline Plans Could Be A Game Changer For Apogee Therapeutics (APGE) - Yahoo Finance
Apogee Therapeutics CMO sells $1.45 million in shares By Investing.com - Investing.com Canada
Apogee Therapeutics CMO Carl Dambkowski Sells Shares - TradingView — Track All Markets
Apogee Therapeutics price target raised to $133 from $95 at Stifel - MSN
What technical signals suggest for Apogee Therapeutics Inc. stockTrade Exit Report & Weekly Hot Stock Watchlists - ulpravda.ru
Can Apogee Therapeutics Inc. stock weather global recessionJuly 2025 Summary & Verified Technical Trade Signals - Улправда
Levels Update: How Apogee Therapeutics Inc. stock reacts to job market data2025 Market Trends & Fast Gaining Stock Strategy Reports - Улправда
Apogee Therapeutics (APGE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
What insider trading reveals about Apogee Therapeutics Inc. stock2025 Winners & Losers & Verified Momentum Stock Alerts - Улправда
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target By Investing.com - Investing.com South Africa
Wolfe Research Initiates Coverage of Apogee Therapeutics (APGE) with Peer Perform Recommendation - Nasdaq
Will Apogee Therapeutics Inc. stock gain from lower inflationMarket Profile Overview & High Yield Portfolio Picks - Улправда
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data - Investing.com Nigeria
March 20th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
Apogee Therapeutics Inc Stock Analysis and ForecastInstitutional Holding Changes & High Yield Trading Signals - earlytimes.in
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target - Investing.com
Apogee Therapeutics CFO Sells 8,000 Shares - TradingView — Track All Markets
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating - Investing.com Nigeria
Apogee Therapeutics stock price target raised to $137 by BTIG on asthma data - Investing.com South Africa
One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Shares Gap DownWhat's Next? - MarketBeat
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose - MarketBeat
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data By Investing.com - Investing.com South Africa
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data - Investing.com Nigeria
Apogee Therapeutics stock falls after asthma trial data By Investing.com - Investing.com South Africa
Apogee Therapeutics Announces Positive Interim Data from Phase 1b Trial of Zumilokibart - TradingView — Track All Markets
Apogee Therapeutics to report interim asthma trial results By Investing.com - Investing.com Nigeria
Apogee Therapeutics Reports Positive Phase 1b Data For Zumilokibart In Mild-to-moderate Asthma - Nasdaq
Apogee Therapeutics rises as asthma drug shows promise in early trial - TradingView — Track All Markets
Apogee Therapeutics Reports Positive Phase 1b Interim Results for Zumilokibart (APG777) in Mild-to-Moderate Asthma and Highlights 2026 Development Milestones - Quiver Quantitative
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - Chartmill
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - Sahm
Apogee Therapeutics to report interim asthma trial results - Investing.com India
User - FinancialContent
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $128.00 - MarketBeat
(APGE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Apogee Therapeutics (APGE) Stock Analysis Report | Financials & Insights - Benzinga
Is Apogee Therapeutics Inc a good long term investmentDay Trading Setups & High Return Trading Portfolio - earlytimes.in
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Apogee Therapeutics Earnings Notes - Trefis
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com India
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.56%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):